Equities

Ondine Biomedical Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Ondine Biomedical Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)9.48
  • Today's Change0.225 / 2.43%
  • Shares traded95.35k
  • 1 Year change-21.04%
  • Beta0.5226
Data delayed at least 20 minutes, as of Feb 17 2026 14:25 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Ondine Biomedical Inc. is a Canadian life sciences company. The Company specializes in light-activated antimicrobial therapies (photo disinfection) for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. The Company has a pipeline of investigational products, based on its proprietary photo disinfection technology, in various stages of development. The Company's nasal photo disinfection system has a CE mark in Europe and is approved in Canada, Australia, Mexico and several other countries under the name Steriwave. In the United States, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is undergoing clinical trials for regulatory approval. Its products beyond nasal photo disinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, serious burns, chronic wounds, central line bloodstream infections and other indications.

  • Revenue in GBP (TTM)1.19m
  • Net income in GBP-12.86m
  • Incorporated1996
  • Employees43.00
  • Location
    Ondine Biomedical Inc888-1100 Melville StVANCOUVER V6E 4A6CanadaCAN
  • Phone+1 (604) 669-0555
  • Fax+1 (604) 669-0555
  • Websitehttps://ondinebio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Verici DX PLC1.40m-5.59m10.22m15.00--0.8987--7.28-0.023-0.0230.00580.00750.2298--1.6778,001.52-91.48---119.40--81.60---398.12------0.102--229.62--32.75------
Genedrive PLC954.00k-5.23m11.33m43.00--4.78--11.87-0.0093-0.00930.00170.00230.1984--1.8022,186.05-108.81-77.52-153.92-106.30-----548.32-1,016.121.64--0.00--90.42-2.0726.06---10.48--
Cellbxhealth PLC2.62m-15.78m11.96m119.00--0.2897--4.56-0.0489-0.04890.00810.03620.10280.59391.4622,050.42-61.80-41.90-72.78-46.8162.2718.55-601.37-1,051.132.63-470.570.2387--30.92--29.34------
Abingdon Health PLC8.43m-3.42m15.06m121.00--2.19--1.79-0.0176-0.01760.04350.02741.179.713.8769,661.16-47.42-54.04-70.70-85.9144.3230.37-40.51-110.071.58--0.1625--37.399.99-168.69---26.92--
Renalytix PLC2.20m-14.97m16.61m45.00------7.54-0.0597-0.05970.008-0.01550.45477.644.54---309.18-83.70---107.2540.0028.27-680.00-1,519.311.17-24.576.38--31.06--55.14------
Inspiration Healthcare Group PLC45.20m-11.44m16.95m214.00--1.04--0.3749-0.1275-0.12750.50380.18261.032.005.91211,215.00-25.96-6.05-33.03-7.4544.3946.62-25.32-7.011.112.420.441--1.6516.56-148.04--39.05--
Aptamer Group PLC1.20m-2.42m24.27m31.00--12.97--20.18-0.0014-0.00140.00070.00070.42946.274.3538,806.45-86.53---154.00--48.13---201.50--1.48-84.630.2622--39.88--18.05------
Aoti Inc46.87m1.73m44.75m80.0021.253.4412.990.95460.01980.01980.47090.12241.322.174.65--4.87--6.54--88.13--3.69--2.542.810.5269--32.88--78.55------
Ondine Biomedical Inc1.19m-12.86m47.97m43.00--105.00--40.45-0.0353-0.03530.00320.00090.34470.57718.03---373.83---4,807.85--65.77---1,084.66--0.7948--0.4333--70.32---32.51------
Creo Medical Group PLC2.20m12.60m69.09m133.005.661.134.9731.400.02960.02720.00560.14770.0319-0.80340.330816,541.3518.25-29.2520.62-35.8945.4547.22572.73-176.824.75-69.500.0645--0.00212.28-17.30---18.58--
Inspecs Group PLC192.83m-3.31m76.76m1.65k--0.86158.220.3981-0.0326-0.08061.900.87640.91382.317.71116,586.50-1.57-2.16-2.31-3.1351.8649.60-1.72-2.790.88471.730.3969---2.4832.80-362.19--4.97--
SDI Group PLC69.29m4.59m88.89m504.0019.771.739.801.280.0430.0430.64970.49230.7692--5.78137,484.105.127.085.818.87--63.936.658.601.195.750.33630.000.502721.99-5.848.9911.55--
EKF Diagnostics Holdings PLC50.22m6.12m111.45m297.0019.111.6210.142.220.01350.01350.11090.15970.62093.167.34165,745.907.985.798.776.7649.7949.4212.868.623.47--0.0152---4.592.25165.3911.163.02--
Data as of Feb 17 2026. Currency figures normalised to Ondine Biomedical Inc's reporting currency: UK Pound GBX

Institutional shareholders

26.76%Per cent of shares held by top holders
HolderShares% Held
M&G Investment Management Ltd.as of 03 Sep 202567.25m12.97%
Janus Henderson Investors UK Ltd.as of 30 Jun 202550.27m9.70%
Chelverton Asset Management Ltd.as of 30 Jun 202516.00m3.09%
Premier Fund Managers Ltd.as of 31 Oct 20255.17m1.00%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.